| DLBCL is one of most common entity in NHL, its morphology, immunophenotype,genetics and clinical presentation have obvious heterogeneity. It is reported that combinedchemotherapy is effective in50%of DLBCL patients while there are still a portion ofpatients did not benefit from it. Presently, IPI is widely used to assess prognosisinternationally. However, different patients have varied prognosis even if they have the sameIPI. If we can find more effective factor to assess prognosis and recurrence, recognizepatients with high risk and treat them actively, we will help to improve the treatment andprognosis. As the pathological basis of tumor is revealing, the importance of CD5and CD43in the generation of malignant tumor are recognized and become significant biologicalfactors. Only few reports on this have been published abroad while there is no definite onesin our country. We explored the expression of CD5and CD43in DLBCL and its clinicalsignificance in this article. To analyze the expression of CD5and CD43in diffuse large Bcell lymphoma (DLBCL) and explore its relationship with the clinicopathologicalcharacteristic providing evidence for analysis of disease and therapy. The clinical data from160DLBCL patients who were treated in First Bethune hospital of Jilin University fromJanuary2001to December2010were retrospectively analyzed. Immunohistochemicalstaining for CD5and CD43was performed on the paraffin-embedded tissue. To analyse thefinal data by SPSS18.0software, analyse the expression of CD5、CD43and their relationshipthrough Spearman test,the relationship between the clinical pathological characteristic andthe expression of CD5and CD43,relationship between the clinical pathologicalcharacteristic and overall survival time. The results are as follows：1.10.6%of DLBCLpatients are CD5positive and significantly related to the age and sites of involvementoutside lymph node.2.29.3%of DLBCL patients are CD43positive, and significantlyrelated to age, LDH level, immunophenotype, B symptom and sites of involvement outsidelymph node.3.CD5and CD43were positively coexpressed in9cases DLBCL, negativelycoexpressed in105cases. There was a positive correlation between the expression of CD5and CD43in DLBCL.4.The short term therapeutic effects of DLBCL patients are related toage, clinical stage, LDH level, the size of tumor and IPI. Age older than60, clinical stage Ⅲ-Ⅳ, high LDH, large tumor and IPI3-5are related to poor prognosis.5.Cox analysisshowed that clinical stage Ⅲ-Ⅳ、high LDH、 CD5+、CD43+is significantly related to poorshort term therapeutic effects and prognosis. We draw the following conclusions from thisstudy：1. In CD5+DLBCL patients, EFS and OS are significantly lower, ages are older, sitesof involvement outside lymph node are more, and clinical stage and IPI are higher. Thisindicates CD5may involve in the pathogenesis of DLBCL and CD5can be used to tell theprognosis. This indicates CD5may involve in the pathogenesis of DLBCL and CD5can beused to tell the prognosis.2. In CD43+DLBCL patients, EFS and OS are lower, ages areolder, LDH level and ECOG are higher, This indicates CD43may involve in thepathogenesis of DLBCL and CD43can be used to tell the prognosis.3.There was a positivecorrelation between the expression of CD5and CD43in DLBCL,which indicates that theymay play a synergistic role in the development of DLBCL.4. When the age is over60,clinical stage is Ⅲ-Ⅳ, LDH level is high, tumor is large, IPI is between3-5, the prognosis ofDLBCL is poor.5. Multiple factor analysis showed that clinical stage, LDH level, CD5andCD43expression are independent prognostic factors of DLBCL and are important forevaluation of patients condition and individual therapy. We should especially pay attentionto the CD5+and CD43+patients directing the proper treatment. |
PDF Full Text Request